首页> 外文期刊>Virology Journal >Multiple linear epitopes (B-cell, CTL and Th) of JEV expressed in recombinant MVA as multiple epitope vaccine induces a protective immune response
【24h】

Multiple linear epitopes (B-cell, CTL and Th) of JEV expressed in recombinant MVA as multiple epitope vaccine induces a protective immune response

机译:JEV的多个线性表位(B细胞,CTL和Th)在重组MVA中表达,因为多个表位疫苗诱导保护性免疫应答

获取原文
           

摘要

Epitope-based vaccination might play an important role in the protective immunity against Japanese encephalitis virus (JEV) infection. The purpose of the study is to evaluate the immune characteristics of recombinant MVA carrying multi-epitope gene of JEV (rMVA-mep). The synthetic gene containing critical epitopes (B-cell, CTL and Th) of JEV was cloned into the eukaryotic expression vector pGEM-K1L, and the rMVA-mep was prepared. BALB/c mice were immunized with different dosages of purified rMVA-mep and the immune responses were determined in the form of protective response against JEV, antibodies titers (IgG1 and IgG2a), spleen cell lymphocyte proliferation, and the levels of interferon-γ and interleukin-4 cytokines. The results showed that live rMVA-mep elicited strongly immune responses in dose-dependent manner, and the highest level of immune responses was observed from the groups immunized with 107 TCID50 rMVA-mep among the experimental three concentrations. There were almost no difference of cytokines and neutralizing antibody titers among 107 TCID50 rMVA-mep, recombinant ED3 and inactivated JEV vaccine. It was noteworthy that rMVA-mep vaccination potentiates the Th1 and Th2-type immune responses in dose-dependent manner, and was sufficient to protect the mice survival against lethal JEV challenge. These findings demonstrated that rMVA-mep can produce adequate humoral and cellular immune responses, and protection in mice, which suggested that rMVA-mep might be an attractive candidate vaccine for preventing JEV infection.
机译:基于表位的疫苗接种可能在针对日本脑炎病毒(JEV)感染的保护性免疫中发挥重要作用。本研究的目的是评估携带JEV多表位基因(rMVA-mep)的重组MVA的免疫特性。将含有JEV关键表位(B细胞,CTL和Th)的合成基因克隆到真核表达载体pGEM-K1L中,制备了rMVA-mep。用不同剂量的纯化rMVA-mep免疫BALB / c小鼠,并以对JEV,抗体滴度(IgG1和IgG2a),脾细胞淋巴细胞增殖以及干扰素-γ和白细胞介素4细胞因子。结果表明,活的rMVA-mep以剂量依赖性方式引起强烈的免疫反应,并且在用10 7 TCID 50 免疫的组中观察到最高水平的免疫反应。 rMVA-mep在实验的三个浓度中。 10 7 TCID 50 rMVA-mep,重组ED3和灭活JEV疫苗之间的细胞因子和中和抗体滴度几乎没有差异。值得注意的是,rMVA-mep疫苗接种以剂量依赖的方式增强了Th1和Th2型免疫应答,足以保护小鼠免受致命JEV攻击。这些发现表明,rMVA-mep可以在小鼠中产生足够的体液和细胞免疫反应,并具有保护作用,这表明rMVA-mep可能是预防JEV感染的有吸引力的候选疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号